Islet-specific antibody seroconversion in patients with long duration of permanent neonatal diabetes caused by mutations in the KCNJ11 gene

Diabetes Care

Volumn 30, Issue 8, 2007, Pages 2080-2082

  Gach, Agnieszka ^a   Wyka, Krystyna ^a   Malecki, Maciej T ^b   Noczynska, Anna ^c   Skupien, Jan ^b   Nazim, Joanna ^d   Szalecki, Mieczyslaw ^e   Bodalski, Jerzy ^a   Sieradzki, Jacek ^b   Mlynarski, Wojciech ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b JAGIELLONIAN UNIVERSITY   (Poland)

^c WROCLAW MEDICAL UNIVERSITY   (Poland)

^d JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^e Children's Hospital   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

PANCREAS ISLET CELL ANTIBODY; VOLTAGE GATED POTASSIUM CHANNEL;

ADOLESCENT; ADULT; ANTIBODY TITER; ARTICLE; CHILD; CLINICAL ARTICLE; DISEASE DURATION; FEMALE; GENE; GENE MUTATION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KCNJ11 GENE; MALE; ONSET AGE; PERMANENT NEONATAL DIABETES; SEROCONVERSION;

AMINO ACID SUBSTITUTION; AUTOANTIBODIES; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; ISLETS OF LANGERHANS; MALE; MUTATION; POLAND; POLYMORPHISM, SINGLE NUCLEOTIDE; POTASSIUM CHANNELS, INWARDLY RECTIFYING; REGISTRIES;

EID: 34547658007     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc06-2440     Document Type: Article

References (14)

1. Gloyn AL, Pearson ER, Antcliff JF, Proks P, Bruining GJ, Slingerland AS, Howard N, Srinivasan S, Silva JM, Molnes J, Edghill EL, Frayling TM, Temple IK, Mackay D, Shield JP, Sumnik Z, van Rhijn A, Wales JK, Clark P, Gorman S, Aisenberg J, Ellard S, Njolstad PR, Ashcroft FM, Hattersley AT: Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med 350:1838-1849, 2004
2. Pearson ER, Flechtner I, Njølstad PR, Malecki MT, Flanagan SE, Larkin B, Ashcroft FM, Klimes I, Codner E, Iotova V, Slingerland AS, Shield J, Robert JJ, Holst JJ, Clark PM, Ellard S, Søvik O, Polak M: Hattersley AT, the Neonatal Diabetes International Collaborative Group: Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 355:467-477, 2006
3. Vaxillaire M, Populaire C, Busiah K, Cave H, Gloyn AL, Hattersley AT, Czernichow P, Froguel P, Polak M: Kir6.2 mutations are a common cause of permanent neonatal diabetes in large cohort of french patients. Diabetes 53:2719-2722, 2004
4. Sagen JV, Raeder H, Hathout E, Shehadeh N, Gudmundsson K, Baevre H, Abuelo D, Phornphutkul C, Molnes J, Bell GI, Gloyn AL, Hattersley AT, Molven A, Sovik O, Njolstad PR: Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: patient characteristics and initial response to sulfonylurea therapy. Diabetes 53:2713-2718, 2004
5. Massa O, Iafusco D, D'Amato E, Gloyn AL, Hattersley AT, Pasquino B, Tonini G, Dammacco F, Zanette G, Meschi F, Porzio O, Bottazzo G, Crino A, Lorini R, Cerutti F, Vanelli M, Barbetti F, Early Onset Diabetes Study Group of the Italian Society of Pediatric Endocrinology and Diabetology: KCNJ11 activating mutations in Italian patients with permanent neonatal diabetes. Hum Mutat 25:22-27, 2005
6. Tonini G, Bizzarri C, Bonfanti R, Vanelli M, Cerutti F, Faleschini E, Meschi F, Prisco F, Ciacco E, Cappa M, Torelli C, Cauvin V, Tumini S, Iafusco D, Barbetti F, Early Onset Diabetes Study Group of the Italian Society of Paediatric Endocrinology and Diabetology: Sulfonylurea treatment outweighs insulin therapy in short-term metabolic control of patients with permanent neonatal diabetes mellitus due to activating mutations of the KCNJ11 (KIR6.2) gene. Diabetologia 49:2210-2213, 2006
7. Skupien J, Malecki MT, Mlynarski W, Klupa T, Wanic K, Gach A, Solecka I, Sieradzki J: Assessment of insulin sensitivity in adult subjects with permanent neonatal diabetes mellitus due to mutations in the KCNJ11 gene encoding Kir6.2. Rev Diabetic Stud 3:17-20, 2006
8. Malecki MT, Skupien J, Klupa T, Wanic K, Mlynarski W, Gach A, Solecka I, Sieradzki J: Transfer to sulphonylurea therapy of adult subjects with permanent neonatal diabetes due to KCNJ11 activating mutations: evidence for improvement in insulin sensitivity. Diabetes Care 30:147-149, 2007
9. Horwitz MS, Ilic A, Fine C, Rodriguez E, Sarvetnick N: Presented antigen from damaged pancreatic beta cells activates autoreactive T cells in virus-mediated autoimmune diabetes. J Clin Invest 109:79-87, 2002
10. Faideau B, Larger E, Lepault F, Carel JC, Boitard C: Role of β-cells in type 1 diabetes pathogenesis Diabetes 54 (Suppl. 2):S87-S96, 2005
11. Lipson KL, Fonseca SG, Urano F: Endoplasmic reticulum stress-induced apoptosis and auto-immunity in diabetes. Curr Mol Med 6:71-77, 2006
12. Lee SC, Pervaiz S: Apoptosis in the pathophysiology of diabetes mellitus. Int J Biochem Cell Biol 39:497-504, 2007
13. Lin CW, Lin YW, Yan FF, Casey J, Kochhar M, Pratt EB, Shyng SL: Kir6.2 mutations associated with neonatal diabetes reduce expression of ATP-sensitive K+ channels: implications in disease mechanism and sulfonylurea therapy. Diabetes 55:1738-1746, 2006
14. + channels in neonatal diabetes: implications for pharmacogenomic therapy Diabetes 54:2645-2654, 2005